$119.99
YK-11 SARM
YK-11 SARM is a synthetic, steroidal selective androgen receptor modulator studied for its unique molecular activity in laboratory settings. Unlike traditional anabolic steroids, YK-11 has attracted scientific interest due to its potential dual role in androgen receptor modulation and myostatin pathway influence.
It is important to note that YK-11 is not FDA-approved, not legally sold as a dietary supplement, and not approved for human consumption. All current knowledge is derived from preclinical research.
This guide explores:
YK-11 is classified as a synthetic steroidal SARM (Selective Androgen Receptor Modulator). It binds selectively to androgen receptors in muscle tissue in experimental models, distinguishing it from non-selective anabolic steroids.
YK-11’s molecular structure allows it to act as a partial agonist of the androgen receptor while potentially influencing muscle growth signaling pathways.
YK-11 selectively binds to androgen receptors (AR) in skeletal muscle cells in vitro. This receptor interaction may activate anabolic signaling pathways associated with muscle differentiation and growth.
In preclinical comparisons, SARMs are studied for their potential tissue-selective activity, meaning they may influence muscle tissue differently than traditional anabolic steroids.
One of the most discussed aspects of YK-11 research is its potential interaction with myostatin.
This dual pathway (androgen receptor modulation + possible myostatin suppression) makes YK-11 unique among experimental SARMs.
Preclinical bone tissue models suggest possible anabolic effects on osteoblast activity. However, these findings are limited to laboratory and animal research, with no validated human data available.
Current research is limited to cell culture and animal studies.
Reported findings include:
These results are experimental and not clinically validated.
There are currently:
Human efficacy, hormonal impact, cardiovascular risk, and liver effects remain unknown.
YK-11 is typically supplied as a lyophilized powder for research use.
Recommended storage conditions:
Reconstitution should be conducted using sterile laboratory-grade solvents according to research protocols.
Preclinical dosing varies significantly depending on study design and biological model. Translating laboratory dosing to humans is not scientifically validated.
No safe or recommended human dosage exists.
YK-11:
Regulatory treatment varies by country, and possession or sale may be restricted depending on jurisdiction.
Because YK-11 lacks human clinical trials, safety data are limited.
Potential theoretical risks associated with SARMs or steroidal compounds may include:
However, these risks have not been adequately studied in controlled human trials for YK-11 specifically.
Unsupervised or off-label use carries significant legal and health risks.
YK-11 is investigated in laboratory settings for:
These applications are exploratory and not clinical recommendations.
YK-11 SARM is an experimental steroidal selective androgen receptor modulator studied for its potential dual mechanism involving androgen receptor binding and myostatin pathway interaction.
Although early laboratory research suggests interesting anabolic signaling activity, all available evidence is limited to in vitro and animal studies. There are no validated human clinical trials confirming safety, dosing, or efficacy.
For accuracy and compliance, discussions of YK-11 should remain focused on:
YK-11 remains a laboratory research compound and is not approved for therapeutic, dietary, or performance use.
